Cancer and Inflammation: A Complex Interplay with Emerging Therapies

For nearly two centuries, the link between inflammation and cancer has been recognized. Initially observed by Rudolf Virchow in the 19th century, this connection is now firmly established, with research demonstrating that inflammation plays a critical role in all stages of cancer development—from initiation to progression and metastasis. Approximately 20% of cancers are linked to chronic infections, autoimmune diseases, or environmental factors that induce persistent inflammation.^[3] This article explores the intricate relationship between cancer and inflammation, examining the underlying mechanisms, translational advances and emerging clinical strategies.

Mechanistic Insights into the Cancer-Inflammation Axis

The interplay between cancer and inflammation is driven by complex signaling pathways and the activity of various immune cells. Understanding these mechanisms is crucial for developing effective therapeutic interventions.

Signaling Pathways

Key signaling pathways, such as NF-κB and STAT3, are frequently activated in cancer cells and promote cell survival, angiogenesis (the formation of new blood vessels), and immunosuppression.^[2] The COX-2/PGE2 pathway also contributes to cancer progression by driving proliferation and recruiting myeloid-derived suppressor cells (MDSCs).^[2]

Immune Cell Dynamics

Inflammation involves a complex interplay of immune cells. Tumor-associated macrophages (TAMs), particularly those polarized towards the M2 phenotype, MDSCs, regulatory T cells (Tregs), and N2 neutrophils often suppress anti-tumor immunity, creating a tumor-permissive microenvironment.^[3] Recent single-cell analyses have revealed the heterogeneity of these immune cell populations and identified potential therapeutic targets.^[2]

Additional Pathways

The NLRP3 inflammasome, a multi-protein complex involved in inflammatory responses, and epigenetic modifications contribute to the perpetuation of inflammatory cycles in cancer.^[2]

Cancer-Specific Examples

• Colorectal Cancer (CRC): Dysbiosis (imbalance in gut bacteria), activation of NF-κB/STAT3, and NLRP3 inflammasome activation are correlated with poor prognosis.^[2]
• Lung Cancer: Exposure to tobacco smoke and air pollution triggers COX-2/PGE2 and IL-6/STAT3 signaling, while KRAS mutations can amplify immunosuppression.^[2]
• Breast Cancer: Obesity-associated inflammation promotes the accumulation of MDSCs and Tregs, and C-reactive protein (CRP) levels can predict response to neoadjuvant therapy.^[2]

Immunotherapy and Inflammation

Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment, but responses remain variable. Inflammation plays a significant role in both the efficacy and resistance to immunotherapy.

Checkpoint Inhibitors

Anti-PD-1/PD-L1 and anti-CTLA-4 therapies achieve response rates of 20–40% in many cancers. Elevated levels of IL-6 have been associated with resistance to these therapies.^[2] Relatlimab, a LAG-3 blockade, was approved in 2024.^[2]

CAR-T Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in hematologic malignancies. However, its effectiveness in solid tumors is limited by the immunosuppressive tumor microenvironment (TME). CRISPR-edited CAR-T cells are being developed to improve persistence in inflammatory TMEs.^[2]

Vaccines and Oncolytic Viruses

Personalized neoantigen vaccines and oncolytic viruses, such as talimogene laherparepvec, are under investigation. Combining these approaches with anti-inflammatory agents is being explored to enhance their efficacy.^[2]

TILs

Tumor-infiltrating lymphocytes (TILs) have demonstrated efficacy in melanoma treatment, and CRISPR enhancement strategies are in development.^[2]

Translational Advances and Clinical Strategies

Several strategies are being explored to target inflammation in cancer therapy, including drug repurposing, cytokine targeting, and inhibition of key signaling pathways.

Drug Repurposing

Aspirin has been shown to reduce the risk of CRC and metastasis. COX-2 inhibitors are used in the treatment of familial adenomatous polyposis (FAP), and statins are under investigation for their potential anti-cancer effects.^[2]

Cytokine Targeting

Clinical trials are evaluating the use of tocilizumab (anti-IL-6R), siltuximab (anti-IL-6), and infliximab (anti-TNF) to block inflammatory cytokines. Studies in 2025 are combining IL-6 blockade with ICIs in pancreatic cancer.^[2]

NF-κB/STAT3 Inhibition

Bortezomib, a proteasome inhibitor, suppresses NF-κB activation. Novel STAT3 inhibitors are showing promise in preclinical studies by reducing MDSCs.^[2]

Biomarkers for Predicting Response

Inflammatory biomarkers, such as CRP, IL-6, neutrophil-to-lymphocyte ratio (NLR), and the pan-immune-inflammation value (PIV), can predict prognosis and response to immunotherapy.^[3] PD-L1 IHC, tumor mutational burden (TMB), and microsatellite instability (MSI) are also used as predictive biomarkers. Emerging biomarkers include circulating tumor DNA (ctDNA) and microbiome signatures.^[2]

Future Perspectives

Emerging technologies, including microbiome modulation, artificial intelligence (AI), gene editing, and single-cell omics, hold promise for refining precision therapy and overcoming resistance to cancer treatment.

Microbiome Modulation

Certain bacterial species, such as Bifidobacterium and Akkermansia, have been correlated with improved response to immunotherapy. Fecal microbiota transplantation (FMT) and CRISPR-based editing of the gut microbiome are under investigation.^[2]

AI and Machine Learning

AI and machine learning algorithms are being developed to predict prognosis, identify patients most likely to benefit from CAR-T cell therapy, and integrate imaging and text data for more accurate diagnosis and treatment planning.^[2]

Gene Editing

CRISPR-Cas9 gene editing is being used to modify exhaustion genes in CAR-T cells and RNA editing offers reversible modulation of gene expression.^[2]

Conclusion

Chronic inflammation is a key driver of tumorigenesis, immune evasion, and therapy resistance. Integrating inflammation-targeting strategies with immunotherapy and biomarker-guided approaches offers a promising path towards personalized cancer care. Continued advances in microbiome modulation, AI, gene editing, and single-cell technologies are poised to transform the field of cancer therapy.